Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review

11 Citationer (Scopus)
63 Downloads (Pure)

Abstract

Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adenocarcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation studies are needed.
OriginalsprogEngelsk
Artikelnummer5020008
TidsskriftEpigenomes
Vol/bind5
Udgave nummer2
ISSN2075-4655
DOI
StatusUdgivet - 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Cell-Free DNA Methylation as Blood-Based Biomarkers for Pancreatic Adenocarcinoma—A Literature Update'. Sammen danner de et unikt fingeraftryk.

Citationsformater